NCT05839392招募中不适用
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable
研究概览
简要总结
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
详细描述
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AML with MECOM or atypical 3q26 rearrangements.
- •Signed written informed consent according to ICH/EU/GCP and national local laws.
排除标准
- 未提供
结局指标
主要结局
Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable
时间窗: At baseline
To assess the number of regulators or effectors of MECOM/EVI1
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
BAY86-9766 Plus Gemcitabine Phase I Study in AsianNeoplasmsNCT01764828Bayer23
进行中（未招募）
2 期
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaMetastatic MelanomaNCT03149029Massachusetts General Hospital16
已完成
1 期
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV MelanomaUnresectable Stage III or Stage IV MelanomaNCT00412828CuraGen Corporation117
已完成
1 期
MCS110 With BRAF/MEK Inhibition in Patients With MelanomaMelanomaNCT03455764Dana-Farber Cancer Institute6
已完成
3 期
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)Metastatic NSCLCNCT06159790Sandoz218